A Study to Assess the Role of Fenofibrate in Preventing Ischemic Cholangiopathy After Liver Transplantation

Inclusion Criteria:

• Patients who have undergone Donation after Circulatory Death (DCD) livertransplantation (LT).

• At least one serum alkaline phosphatase level >2.5x upper limit of normal betweenpost-LT days 21-60 (inclusive).

Exclusion criteria:

• LT performed for primary sclerosing cholangitis or primary biliary cholangitis.

• Untreated hepatic artery compromise (e.g thrombosis, stenosis)

• Untreated biliary anastomotic stricture or bile leak between days 0-60 after LT

• Renal dysfunction defined as baseline glomerular filtration rate < 30 ml/min.

• Previously known intolerance or allergy to fenofibrate.

• Other clinically significant comorbid condition, including psychiatric conditions,which in the opinion of the study team, may interfere with patient treatment,safety, assessment, or compliance with the treatment.